Log in

NASDAQ:CELG - Celgene Stock Price, Forecast & News

$108.24
0.00 (0.00 %)
(As of 11/22/2019)
Today's Range
$108.24
Now: $108.24
$108.24
50-Day Range
$104.39
MA: $108.21
$110.61
52-Week Range
$58.59
Now: $108.24
$110.70
Volume114,302 shs
Average Volume6.77 million shs
Market Capitalization$77.04 billion
P/E Ratio14.22
Dividend YieldN/A
Beta1.41
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.88 per share
Book Value$16.98 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$77.04 billion
Next Earnings Date1/30/2020 (Estimated)
OptionableOptionable

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.


Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 24th 2018, which authorizes the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 5.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.70 by $0.29. The biopharmaceutical company earned $4.52 billion during the quarter, compared to analysts' expectations of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. Celgene's revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 EPS. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Celgene.

What price target have analysts set for CELG?

18 Wall Street analysts have issued 12 month price targets for Celgene's stock. Their forecasts range from $77.00 to $115.00. On average, they expect Celgene's stock price to reach $97.56 in the next year. This suggests that the stock has a possible downside of 9.9%. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 18 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene’s lead drug, Revlimid, continues to drive revenues on label expansions and market share gains. Robust performance of psoriasis drug, Otezla, is also boosting performance. The focus is on the merger announcement with large-cap pharma Bristol-Myers worth a whopping $74 billion. Per the terms, Celgene shareholders will receive $50 plus one share of Bristol-Myers and one tradeable Contingent Value Right, which will entitle the holder to receive a cash payment of $9.00 upon the achievement of FDA approval of three candidates (ozanimod, liso-cel and bb2121) within the specified time periods. Meanwhile, the company is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. Shares have outperformed the industry in the year so far. Estimates are stable ahead of the second-quarter results." (7/23/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019)

Has Celgene been receiving favorable news coverage?

Media headlines about CELG stock have been trending somewhat negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celgene earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Celgene.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), NVIDIA (NVDA), Bank of America (BAC), Skechers USA (SKX), Integrated Device Technology (IDTI), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Intel (INTC).

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 50)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
  • Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)

Who are Celgene's major shareholders?

Celgene's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (4.19%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Boussard & Gavaudan Investment Management LLP (0.36%), York Capital Management Global Advisors LLC (0.34%), Parametric Portfolio Associates LLC (0.32%) and Assenagon Asset Management S.A. (0.32%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael D Casey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Close Asset Management Ltd, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Voloridge Investment Management LLC, Trillium Asset Management LLC, Stifel Financial Corp and York Capital Management Global Advisors LLC. Company insiders that have sold Celgene company stock in the last year include James J Loughlin and Terrie Curran. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Twin Securities Inc., Soros Fund Management LLC, California Public Employees Retirement System, Tibra Equities Europe Ltd, Boussard & Gavaudan Investment Management LLP, Syquant Capital Sas, ARP Americas LP and Alpine Group USVI LLC. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $108.24.

How big of a company is Celgene?

Celgene has a market capitalization of $77.04 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.View Additional Information About Celgene.

What is Celgene's official website?

The official website for Celgene is http://www.celgene.com/.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  2,002 (Vote Outperform)
Underperform Votes:  778 (Vote Underperform)
Total Votes:  2,780
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel